NCT03452033View on ClinicalTrials.gov

H-1337 Ophthalmic Solution Phase 1/2

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

March 15, 2018

Primary Completion Date

August 15, 2018

Study Completion Date

August 15, 2018

Conditions
Glaucoma, Open-Angle
Interventions
DRUG

H-1337 Placebo

H-1337 Placebo Vehicle

DRUG

H-1337 [1]

H-1337 Ophthalmic Solution Concentration 1

DRUG

H-1337 [2]

H-1337 Ophthalmic Solution Concentration 2

DRUG

H-1337 [3]

H-1337 Ophthalmic Solution Concentration 3

Trial Locations (1)

29445

PRN, Goose Creek

Sponsors
All Listed Sponsors
lead

Allysta Pharmaceutical

INDUSTRY

NCT03452033 - H-1337 Ophthalmic Solution Phase 1/2 | Biotech Hunter | Biotech Hunter